摘要
目的比较多西紫杉醇联合顺铂和培美曲塞联合顺铂治疗晚期非小细胞肺癌的近期疗效和毒性反应。方法选择72例经病理学或细胞学确诊的晚期非小细胞肺癌患者,分两组进行化疗。PC组:培美曲塞500mg·m-2第1天静脉滴注,顺铂75mg·m-2第1～3天,21天为一周期;DP组:多西紫杉醇75mg·m-2,第1天、第8天,静脉滴注1h,顺铂75mg·m-2,分3天于第1～3天静脉滴注,21天为一周期。结果两组有效率、疾病控制率、一年生存率及临床受益反应等无显著统计学差异(P>0.05)。DP组与PC组之间的无进展生存期有显著性差异(P<0.05)。两组毒副反应的发生率差异无明显统计学意义(P>0.05)。结论两种化疗方案治疗晚期非小细胞肺癌均具有较好的近期疗效,并发的毒副反应均可耐受。培美曲塞联合顺铂较多西紫杉醇联合顺铂疗效更好,可作为晚期非小细胞肺癌的首选治疗方案。
Objective To evaluate the short-term efficacy and adverse reactions of docetaxel-pluscisplatin treatment and pemetrexed-plus-cisplatin treatment on elderly advanced non-small cell lung cancer （NSCLC）.Method 72 patients with advanced NSCLC were divided into two groups and performed chemotherapy.Patients in PC group were treated with pemetrexed plus cisplatin （pemetrexed 500 mg·m^-2,intravenous infusion,D1,cisplatin 75 mg·m^-2,intravenous infusion,D1～3,21 days for a cycle）.Patients in DP group were treated with docetaxel plus cisplatin （docetaxel 75 mg·m^-2,intravenous infusion,D1,D8,cisplatin 75 mg·m^-2,intravenous infusion,D1～3,21 days for a cycle）.Results There were no significant difference in the effective rate,disease control rate,year survival rate,clinical benefit response between two groups（P〉0.05）.The median progression-free survival was significantly longer in PC group than DP group（P〈0.05）.In addition,no significant difference was observed in the incidence of adverse reactions after chemotherapy（P〉0.05）.Conclusion Two kinds of chemotherapy both had good clinical efficacy in the treatment of NSCLC.All the adverse reactions caused by toxic medium were able to be tolerated.The clinical efficacy of PC group was better than the DP group,so it could be chosen as the preferred alternative in the treatment of advanced NSCLC.
出处
《肿瘤药学》
CAS
2011年第4期359-362,378,共5页
Anti-Tumor Pharmacy
关键词
多西紫杉醇
培美曲塞
顺铂
晚期肺小细胞肺癌
化疗
Docetaxel
Pemetrexed
Cisplatin
Advanced non-small cell lung cancer
Chemotherapy
